Scientific discoveries and milestones.
1992
The Swedish mutation, which leads to early development of Alzheimer’s disease, was discovered in a Swedish family by Professor Lars Lannfelt
2000
US patent application filed on the discovery of the Arctic mutation, and its propensity to form amyloid-beta oligomers/protofibrils a target for drug intervention
2001
The discovery of the Arctic mutation was published. The Arctic mutation leads to increased production of amyloid-beta oligomers/protofibrils and early development of Alzheimer’s disease. This gave an insight into a new target for treatment of Alzheimer’s disease: amyloid-beta oligomers/protofibrils
2003
BioArctic Neuroscience AB was founded by Lars Lannfelt and Pär Gellerfors
2004
Karolinska Innovation AB invested in BioArctic (the asset was later transferred to Karolinska Development AB)
Concerning a transgenic mouse model (APPArcSwe), BioArctic filed two important patent applications concerning a transgenic mouse model and a concept patent for antibody treatment of Alzheimer’s disease
2005
The drug candidate mAb158 (precursor to BAN2401) was isolated at Uppsala University, in Sweden
BioArctic and Eisai entered into a research collaboration concerning a disease modifying treatment for Alzheimer’s disease
BioArctic started research on Parkinson’s disease in collaboration with Uppsala University
Uppsala University Holding AB invested in BioArctic
2006
BioArctic was located in own premises in Stockholm, in Sweden
2007
BioArctic and Eisai entered into a license agreement concerning the antibody BAN2401 as a disease modifying treatment of Alzheimer’s disease as a result of the research collaboration agreement of 2005
The second US patent for Alzheimer’s disease was granted
BioArctic filed a patent application concerning the antibody BAN2401
2008
BioArctic and Eisai entered into a second research collaboration concerning a back-up antibody to BAN2401
BioArctic and Swenora Biotech AB entered into a license agreement concerning Swenora’s technology for the treatment of complete Spinal Cord Injuries
BioArctic started the development of a treatment for complete Spinal Cord Injury (SC0806) in collaboration with the department of Neurosurgery at the Karolinska University Hospital, Sweden
2010
The clinical development of BAN2401 was started and SC0806 was granted orphan drug status in the EU
2011
SC0806 was granted orphan drug status in the US
2012
BioArctic received a grant from Vinnova for the clinical development of SC0806
BioArctic signed an extension of the ongoing research collaboration with Eisai on immunotherapy for Alzheimer’s disease
2013
BioArctic’s partner Eisai started a clinical Phase 2b study in the US concerning the drug candidate BAN2401 and the clinical development of BAN2401 was started in Japan
2014
The clinical development of BAN2401 in Alzheimer’s disease was started in Europe
BioArctic received a MEUR 6.4 grant from the EU’s research and development program Horizon 2020 (Grant Agreement No. 643853) as co-financing of a clinical study concerning the treatment of Complete Spinal Cord Injury
BioArctic’s partner Eisai entered into an agreement with Biogen concerning the continued development and commercialization of BAN2401 in Alzheimer’s disease
2015
BioArctic and Eisai entered into a license agreement concerning BAN2401 Back-up, a follow-up project to BAN2401, and a third research collaboration agreement concerning a new disease modifying treatment for Alzheimer’s disease
BioArctic’s research program on Parkinson’s disease received grants from Swedish Vinnova and the EU’s research and development program Horizon2020 (Grant Agreement No. 697790)
BioArctic started a clinical study concerning the treatment of Complete Spinal Cord Injury, SC0806
2016
The company’s name was changed from BioArctic Neuroscience AB to BioArctic AB
BioArctic entered into a collaboration agreement with AbbVie concerning research on Parkinson’s disease
2017
The patent for BAN2401 backup was granted in the US
BioArctic received two grants from Swedish Vinnova for the company’s work with the quality management system and the commercial potential of antibody-based PET imaging
Trading in BioArctic’s B-shares commenced October 12th on Nasdaq Stockholm
BioArctic’s patent for its product candidate antibody BAN0805, for Parkinson’s disease, was granted in Europe
2018
Positive BAN2401 Phase 2b clinical study results in early Alzheimer’s disease
Exclusive rights to develop the antibody AD1801 (in discovery) for Alzheimer’s disease
Expanded research collaboration with Uppsala University, Sweden, concerning antibody-based diagnostic imaging of the brain in Alzheimer patients
Research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop new diagnostics for Alzheimer’s disease
Out-licensing of the portfolio of antibodies targeting alpha-synuclein to AbbVie for Parkinson’s disease and other potential indications
Granted concept patent in Europe for treatment strategy for disease-modifying treatment of Parkinson’s disease
Grant from EU’s Horizon 2020 for participation in research consortium for better diagnostic tools and biomarkers for Parkinson’s disease
Inclusion completed of patients with complete spinal cord injury in the first panel of the on-going study with SC0806
Approvals from regulatory authorities and ethics committees to include patients with complete spinal cord injuries from Estonia, Norway and Finland in the study with SC0806
US patent protection for a method with a medical device for treatment of patients with complete spinal cord injury
Patent protection in Japan and EU for a medical device treatment of patients with complete spinal cord injury
Extended research collaboration with Uppsala University regarding new antibody technologies for increased passage across the blood-brain barrier (BBB-technology)
